What is the price target for ITOS stock?
10 analysts have analysed ITOS and the average price target is 10.56 USD. This implies a price increase of 4% is expected in the next year compared to the current price of 10.15.
NASDAQ:ITOS • US46565G1040
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ITEOS THERAPEUTICS INC (ITOS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-28 | Wedbush | Downgrade | Outperform -> Neutral |
| 2025-05-28 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-05-14 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-05-14 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-05-14 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-14 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-05-13 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-04-29 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-03-06 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-03-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-03-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-19 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-12-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | Wells Fargo | Initiate | Overweight |
| 2024-08-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-13 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-10-18 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-08-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 267.6M -22.39% | 12.595M -95.29% | 35M 177.89% | -100.00% | 6.884M | -100.00% | 3.337M | 357K -89.30% | 6.324M 1,671.43% | |||
| EBITDA YoY % growth | 127.1M -48.23% | -150.203M -218.18% | -158.29M -5.38% | -125.46M 20.74% | -95.88M 23.58% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 126.3M -48.43% | -151.101M -219.64% | -159.528M -5.58% | -179.905M -12.77% | -104.5M 41.91% | -169.098M -61.82% | -164.64M 2.64% | -167.405M -1.68% | -170.272M -1.71% | -92.099M 45.91% | -97.569M -5.94% | |
| Operating Margin | 47.20% | -1,199.69% | -455.79% | N/A | -1,518.01% | N/A | N/A | N/A | -5,102.54% | -25,798.00% | -1,542.84% | |
| EPS YoY % growth | N/A -50.69% | -3.15 -213.87% | -3.33 -5.71% | -3.58 -7.51% | -2.08 41.81% | -1.84 11.75% | -2.72 -48.13% | -2.73 -0.37% | -2.76 -0.93% | -2.33 15.71% | -2.23 3.95% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.18 -12.10% | -0.43 58.74% | -0.49 38.16% | -0.54 62.02% | -0.56 52.56% | -0.51 -20.00% | -0.05 89.69% | -0.05 90.42% | -0.05 90.32% | -0.06 89.00% |
| Revenue Q2Q % growth | N/A | N/A | 4.709M | N/A | ||||||
| EBITDA Q2Q % growth | -22.44M 53.13% | -22.44M 53.34% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -54.746M -12.19% | -25.24M 48.84% | -17.724M 63.40% | -18.354M 72.79% | -18.482M 66.24% | -19.127M 24.22% | N/A | N/A | N/A | N/A |
All data in USD
10 analysts have analysed ITOS and the average price target is 10.56 USD. This implies a price increase of 4% is expected in the next year compared to the current price of 10.15.
ITEOS THERAPEUTICS INC (ITOS) will report earnings on 2025-11-10, before the market open.
The consensus EPS estimate for the next earnings of ITEOS THERAPEUTICS INC (ITOS) is -1.18 USD and the consensus revenue estimate is 0 USD.
The consensus rating for ITEOS THERAPEUTICS INC (ITOS) is 50 / 100 . This indicates that analysts generally have a neutral outlook on the stock.